FDA Clears Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss

DELRAY BEACH, Fla., Jan. 18, 2023. Cyrano Therapeutics, a biopharmaceutical company developing medicines for patients with hyposmia (smell loss), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials